Search
for

    GlossaryCCR5 antagonist

    blocks HIV entry into cells by targeting the CCR5 receptor

    A CCR5 antagonist, also known as a CCR5 inhibitor or CCR5 blocker, is a type of drug that blocks the CCR5 receptor on the surface of certain cells. This receptor is used by HIV to enter and infect human cells. By blocking CCR5, these drugs can help prevent HIV from spreading within the body, making them an important tool in the treatment of HIV/AIDS.

    Related Terms

    Learn

    5 / 801 results

      learn Cyproterone

      a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

      learn Pyrilutamide

      highly targeted anti-androgen that might have minimal systemic effects

      learn RU58841

      a potent but unapproved and potentially problematic topical anti-androgen

    Research

    5 / 149 results

    Community Join

    5 / 1000+ results

      community Fevipiprant 2019!

       15 upvotes 9 years ago
      The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

      community cb-03-01 research chem (winlevi/clascoterone cream)

      in Technology  3 upvotes 2 years ago
      The user is considering using CB or clascoterone for hair loss, potentially as an alternative to RU. They're also contemplating asking a dermatologist for topical clascoterone cream to apply to their temple.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.